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Type 2 diabetes is an important public health issue, yet adherence to drugs and regular clini-
cal follow-up is still suboptimal. This study aims to evaluate a community pharmacy pro-
gramme for monitoring and enhancing adherence to prescribed pharmacological therapies
and recommended examinations among patients with confirmed diabetes.
Methods
The intervention was conducted in different Italian areas between April 2017 and January
2018. All adult patients who entered a pharmacy with a personal prescription for any antidia-
betic drug and agreed to participate, were interviewed. Those found to be non-adherent
received counselling from the pharmacists. All patients were invited for a follow-up interview
after 3 months.
Results
Overall, 930 patients were enrolled and completed the baseline interview. We found low
rates of non-adherence, ranging from 8% to 13% for prescribed pharmacological therapies,
and 11–29% for the recommended clinical examinations. Non-adherence to oral therapies
was higher among younger and recently diagnosed patients; that to clinical examinations
was higher in men, those with an intermediate duration of diabetes and less educated
patients. Large geographical differences persisted after the adjustment for individual factors.
Only 306 patients (32.9%) returned for the follow-up interview, most of whom were already
adherent at baseline.
PLOS ONE







Citation: Spadea T, Onorati R, Baratta F, Pignata I,
Parente M, Pannacci L, et al. (2021) Monitoring
adherence to pharmacological therapy and follow-
up examinations among patients with type 2
diabetes in community pharmacies. Results from
an experience in Italy. PLoS ONE 16(9): e0256478.
https://doi.org/10.1371/journal.pone.0256478
Editor: Filipe Prazeres, Faculty of Health Sciences -
Universidade da Beira Interior, PORTUGAL
Received: March 25, 2021
Accepted: August 7, 2021
Published: September 7, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0256478
Copyright: © 2021 Spadea et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
information files.
Conclusions
Poor adherence to drugs or clinical examinations is not easy to identify in the usual operating
setting of community pharmacies. Furthermore, the majority of patients did not return for fol-
low-up, making it impossible to evaluate the efficacy of the pharmacists’ counselling. It might
be more effective to plan interventions addressed to specific subgroups of patients or areas.
Introduction
Both the number of people with diabetes and its prevalence are dramatically increasing world-
wide. About 3.4 million Italians are affected by diabetes and, overall, its prevalence is 5%. How-
ever, its distribution is uneven; it is higher in the south of the country than in the north, higher
in poorly educated people than in the highly educated, and higher in men than in women [1].
Due to its burden in terms of social and health costs, the disease represents an important pub-
lic health issue. Despite the increased awareness of diabetes and its complications, a non-negli-
gible number of patients are still undertreated or do not adhere to clinical guidelines [2,3]. The
available literature reports that adherence to drugs ranges from 20% to 80% [4] while adher-
ence to the glycated haemoglobin and cholesterol tests rarely exceeds 70% [3,5–8].
Adherence and persistence to therapies, as well as compliance to regular monitoring and
clinical follow-up are the main tertiary prevention actions associated to better outcomes, a
reduced or delayed onset of complications, and, not least, to reduced expenditure [2,9–13]. As
a consequence, it is of paramount importance that effective strategies to find non-adherent
patients and improve their compliance to guidelines are identified. Community pharmacies
may be one of the settings where these actions can be carried out, as has already been reported
in other studies [14–16].
In Italy, there are more than 19,000 community pharmacies. As nearly every municipality has
at least one pharmacy, which are easily accessible and free of charge, they are used by the popula-
tion as a fast and trustworthy gateway to health services, and as a contact point with the health
care system [17,18]. In 2012, the Piedmont Regional Orders of Pharmacists, Federfarma Pie-
monte and the University of Turin launched an extensive programme aimed to counteract the
negative effects of non-communicable diseases [18–23]. The programme for diabetes was based
upon two main preventive actions: 1. the identification of undiagnosed cases of the disease
among customers of community pharmacies (secondary prevention); and, 2. monitoring and
enhancing adherence to pharmacological treatment and follow-up guidelines among people with
confirmed diabetes (tertiary prevention). We have already reported the general results of the
regional programme [18], and specifically those of the impact of the opportunistic screening [23].
Subsequently, in 2015, the Italian Health Ministry funded a study to assess the transferability and
efficacy of the programme in the setting of community pharmacies in other regional contexts.
In this paper, we report the results of the second action of the preventive programme, with
the twofold objective of monitoring adherence to prescribed drug therapies and to the exami-
nations recommended by clinical guidelines, and assessing the impact of the intervention. We
also discuss the implications of these results in terms of public health.
Materials and methods
Study population and intervention protocol
The intervention was conducted in two regions in Central and Southern Italy (Umbria and
Puglia, respectively). The study involved a territory comprised of three health districts in
Umbria and two provinces in Puglia (Barletta-Andria-Trani (BAT) and Brindisi), that in total
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care for about 1 million inhabitants. The study consisted of two steps: the first was a cross-
sectional survey aimed at identifying patients with diabetes that were non-adherent to either
their prescribed therapies or their regular clinical examinations, and investigating their charac-
teristics; the second step was designed as a follow-up study of all the interviewees (both adher-
ent and non-adherent subjects) to assess the impact of the intervention.
All of the pharmacists operating in private and public community pharmacies in the territo-
ries were invited to participate in the project on a voluntary basis. Those who agreed were
enrolled in a training course on diabetes (conducted by a senior diabetologist) and on the
study procedures and instruments, with special attention being paid to the questionnaires, to
ensure that all pharmacists collected data homogeneously.
Over the period April 2017-January 2018 all adult persons who entered a pharmacy with a
personal prescription for any antidiabetic drug were informed of the aims of the study and
invited to participate. Given the expected low number of daily entries of diabetic patients, no
sampling was applied. Those who agreed gave their written informed consent to be inter-
viewed and followed-up. Individuals that reported that they suffered from type 1 diabetes or
that they were to have their first prescription were excluded. The pharmacists interviewed the
participants in a consultation room within each pharmacy and then invited them to repeat the
interview in the same pharmacy after 3 months, to assess any change.
Adherence to prescribed drug therapies was investigated using a 4-item scale, developed
from the Italian version of the original 8-item Morisky scale [24]. The questionnaire also
enquired as to whether the patient had had access to any emergency room or hospitalization;
asked if he suffered from any comorbidities such as dyslipidaemia, hypertension and heart fail-
ure; and investigated adherence to all classes of medications taken by the patient. A second
questionnaire explored adherence and the correct timing of eight clinical examinations, rec-
ommended by the Italian Association of Diabetologists and the Italian Society of Diabetology
[25]. Finally, we collected information on education, social/family support and household
composition. Educational level, measured as the maximum attained qualification, was catego-
rized in three classes: low, including no formal education and primary school (corresponding
to the UNESCO International Standard Classification of Education 1997 (ISCED97) levels
0–1); medium, i.e. middle and vocational school (ISCED97 levels 2-3C); and high, including
high school and university degrees (ISCED97 levels 3A, 3B, 5 and 6) [26]. Household condi-
tion and social support were represented by two dichotomous variables indicating whether the
patient lived alone and could receive help in case of need. The questionnaires are reported in
the S1 File. All data were collected electronically and stored in a central database.
All individuals who resulted non-adherent (for either drugs or visits) received counselling
on correct medicine taking and the timing for recommended examinations. Moreover, as
agreed with the local representatives of general medicine trade unions and professional orders,
patients who declared that they had not carried out all follow-up checks were referred to their
general practitioner (GP) for possible further checks.
At the end of the project, a short online satisfaction questionnaire was administered to the
pharmacists in order to collect their qualitative evaluations on the effectiveness of the interven-
tion. They were asked to indicate three positive aspects and three negative aspects of the proj-
ect. Furthermore, they could add suggestions for future studies. All the items were free-text
open questions (S2 File).
Outcome definition and recording
A patient with a score of the 4-item scale higher than one was classified as non-adherent to the
prescribed pharmacological therapies; patients using both insulin and oral drugs were
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included in both therapy groups. In the case of clinical examinations, we first considered non-
adherence separately for each item explored. Given that the percentage of patients who
responded positively to all questions was very low (19%) and considering that the recommen-
dations do not have the same clinical weight, we decided to analyse in detail only the measure-
ment of glycated haemoglobin (HbA1c) every 6 months, as this is the main indicator of disease
control. Furthermore, we calculated the Guideline Composite Indicator (GCI), which is a
comprehensive indicator of adherence that has proven to correlate with more favourable
health outcomes [11], and which classifies patients who have not carried out the HbA1c test
and at least two checks from cholesterol, albuminuria and fundus of the eye, as being non-
adherent.
Statistical analysis
We used the Chi squared tests for categorical variables to assess differences across study areas;
a 2-tail p-value of less than 0.05 was considered statistically significant. Determinants of non-
adherence were investigated performing robust Poisson multivariable regression models,
which estimate prevalence ratios (PR) with their 95% confidence intervals (95% CI) [27]. All
statistical analyses were run using SAS-ver.9.3 and STATA-ver.10.
Ethics statement
The study has been approved by the Italian Ministry of Health as part of the CCM (National
Center for Disease Prevention and Control) programme 2015, and, according to Italian legisla-
tion, does not require further evaluation by the Ethics Committee. Nonetheless, the same pro-
tocol had been approved by the "Azienda Sanitaria Locale ASLTO2" Ethics Committee,
Approval Protocol n˚46480/2013 [23].
Results
Overall, at least one pharmacist from 155 out of the 253 (61.3%) pharmacies in the study areas
attended the training course with at least one pharmacist (248 pharmacists completed the
training). Of these, 99 (64% of trained pharmacies) participated in the programme, enrolling
1037 patients. Of these patients, 62 (6%) were affected by Type 1 diabetes and were excluded,
while 45 (4.3%) refused to participate (the complete flow chart is reported in the S3 File).
Table 1 shows the characteristics of the remaining 930 patients, overall and by centre. Men
were 59% of the population, two thirds of participants were over 64 years of age, and about
60% had a duration of diabetes longer than 5 years; 85% had at least one comorbidity. As for
the sociodemographic indicators, 43% were low educated patients, while 20% had at least a
high school diploma. The great majority (about 90%) did not live alone and could receive help
in case of need.
The prevalence of non-adherence to pharmacological therapies and to clinical examina-
tions, according to individual characteristics, are reported in Table 2. Looking at therapies, out
of 261 insulin users (28% of patients entering the pharmacies), only 20 (7.7%) were non-adher-
ent, while among the 836 patients with a prescribed oral therapy (90% of patients) the preva-
lence of non-adherence raised to 12.7%. When comparing insulin and oral drug users, the
distribution of non-adherence resulted reversed for most individual characteristics, making a
pooled analysis impossible. Therefore, given the small number of non-adherent insulin users,
we only focussed on non-adherence to oral drugs in the subsequent analyses; prevalence was
higher among women, younger patients, those with a lower duration of disease, without
comorbidities, and in socially advantaged patients (more educated, who had social support
and who did not live alone).
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Looking at the recommended clinical examinations, around 24% of patients were not
adherent to HbA1c, and similar percentages were observed for albuminuria and the eye exami-
nation; only 11% did not check their cholesterol level. When the comprehensive GCI was con-
sidered, non-adherence increased to 29%. Non-adherence is generally greater in men, in those
without comorbidities and in the less educated patients. With respect to the duration of diabe-
tes, the prevalence has a reversed U-shaped curve, with lowest levels in the newly diagnosed
cases and in those with long durations. Finally, we observed very large geographical differences
in all the indicators of non-adherence, with lower rates in the central area of the country
(Umbria) and the highest in the Brindisi Province.
After the multivariable adjustment (Table 3), non-adherence to oral therapies remained
associated only with age and duration of diabetes, increasing with decreasing age and decreas-
ing duration of the disease. No significant differences emerged with regards to gender or social
indicators. Non-adherence to clinical examinations was significantly higher in men and in
patients with intermediate duration of diabetes. However, a higher risk of non-adherence was
Table 1. Characteristics of the enrolled patients with type 2 diabetes, by study area and overall.
Umbria Region (n = 330) BAT Province (n = 380) Brindisi Province (n = 220) Chi-square ALL (n = 930)
n % n % n % p-value� n %
Gender
Women 126 38.2 156 41.1 96 43.6 0.433 378 40.6
Men 204 61.8 224 58.9 124 56.4 552 59.4
Age
<45 0 0 13 3.4 7 3.2 0.002 20 2.2
45–54 22 6.7 38 10 29 13.2 89 9.6
55–64 71 21.5 89 23.5 50 22.7 210 22.6
�65 237 71.8 239 63.1 134 60.9 610 65.7
Duration of diabetes (years)
<1 22 6.7 29 7.6 16 7.3 0.012 67 7.2
1–5 81 24.6 88 23.2 56 25.4 225 24.2
5–10 81 31.2 102 26.8 58 26.4 241 25.9
>10 103 24.5 142 37.4 78 35.5 323 34.7
Unknown 43 13 19 5 12 5.4 74 8
Comorbidities
Yes 281 85.1 319 83.9 194 88.2 0.363 794 14.6
No 49 14.9 61 16.1 26 11.8 136 85.4
Educational level
High 75 22.7 73 19.2 38 17.3 0.167 186 20
Medium 126 38.2 129 34 89 40.5 344 36.9
Low 129 39.1 178 46.8 93 42.3 400 43.1
Living alone��
Yes 35 10.6 42 11.1 16 7.3 0.296 93 10.1
No 294 89.4 338 88.9 204 92.7 836 89.9
Social network
Yes 312 94.6 351 92.4 192 87.3 0.008 855 91.9
No 18 5.4 29 7.6 28 12.7 75 8.1
� p-value <0.05 indicates a statistical significant difference between areas.
�� 1 case missing.
https://doi.org/10.1371/journal.pone.0256478.t001
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observed among patients who did not report the duration of their disease. Non-adherence was
also higher in the least educated patients. Large geographical differences persisted after the
adjustment for all the other individual factors.
After three months, only 250 patients (26.9% of those invited) returned for a follow-up
interview; if we include the 56 people who returned beyond the time limit, the percentage
increased to 32.9%. Most of the returnees were already adherent at baseline (97% of insulin
users and 91% of oral drug users),yet adherence showed a small increase at follow-up, remain-
ing at 97% among insulin users and reaching 94% among oral drug users. Unfortunately, only
2 non-adherent insulin users and 14 patients non-adherent to oral drugs returned for follow-
Table 2. Number of cases and prevalence of non-adherence to prescribed pharmacological therapies and recommended clinical examinations by patient
characteristics.
Pharmacological therapies Clinical examinations
Insulin Oral therapy HbA1c Cholesterol Albuminuria Fundus eye GCI
(n = 261) (n = 836) (n = 930) (n = 930) (n = 930) (n = 930) (n = 930)
n % n % n % n % n % n % n %
TOTAL 20 7.7 106 12.7 222 23.9 106 11.4 216 23.2 224 24.1 272 29.2
Gender
Women 6 6.2 48 13.8 83 22.0 43 11.4 90 23.8 92 24.3 102 27.0
Men 14 8.5 58 11.9 139 25.2 63 11.4 126 22.8 132 23.9 170 30.8
Age
<45 0 0.0 6 33.3 5 25.0 3 15.0 5 25.0 8 40.0 6 30.0
45–54 1 3.4 20 26.3 17 19.1 8 9.0 21 23.6 29 32.6 27 30.3
55–64 4 7.1 26 13.1 47 22.4 20 9.5 39 18.6 46 21.9 54 25.7
�65 15 8.7 54 9.9 152 24.9 74 12.1 150 24.6 140 23.0 184 30.2
Duration of diabetes (years)
<1 0 0.0 12 18.8 13 19.4 9 13.4 20 29.9 29 43.3 20 29.9
1–5 3 8.3 42 19.8 64 28.4 25 11.1 59 26.2 68 30.2 78 34.7
5–10 5 8.3 18 8.0 63 26.1 34 14.1 62 25.7 57 23.7 77 32.0
>10 12 8.3 27 10.3 66 20.4 33 10.2 55 17.0 48 14.9 73 22.6
Unknown 0 0.0 6 15.4 16 21.6 5 6.8 20 27.0 22 29.7 24 32.4
Comorbidities
Yes 19 8.0 93 12.5 186 23.4 83 10.5 177 22.3 181 22.8 225 28.3
No 1 4.2 13 14.3 36 26.5 23 16.9 39 28.7 43 31.6 47 34.6
Educational level
High 7 12.1 26 15.9 37 19.9 18 9.7 36 19.4 34 18.3 46 24.7
Medium 3 3.6 37 11.7 73 21.2 35 10.2 71 20.6 83 24.1 92 26.7
Low 10 8.4 43 12.1 112 28.0 53 13.3 109 27.3 107 26.8 134 33.5
Living alone
Yes 3 10.7 9 10.7 23 24.7 13 14.0 22 23.7 20 21.5 26 28.0
No 16 6.9 97 12.9 199 23.8 93 11.1 194 23.2 204 24.4 246 29.4
Social network
Yes 20 8.3 101 13.2 209 24.4 95 11.1 199 23.3 199 23.3 253 29.6
No 0 0.0 5 6.9 13 17.3 11 14.7 17 22.7 25 33.3 19 25.3
Study area
BAT 5 5.0 46 13.2 100 26.3 45 11.8 99 26.1 103 27.1 124 32.6
BR 7 10.6 36 18.4 74 33.6 32 14.6 72 32.7 69 31.4 87 39.6
Umbria 8 8.4 24 8.2 48 14.6 29 8.8 45 13.6 52 15.7 61 18.5
https://doi.org/10.1371/journal.pone.0256478.t002
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up. Therefore, the planned evaluation of the effectiveness of counselling for non-adherent
patients cannot be performed.
As a further qualitative evaluation, we analysed the satisfaction questionnaires completed at
the end of the study by almost 70 pharmacists, out of the 99 participating in the programme.
The pharmacists reported general appreciation for having been involved in the project, con-
firming that they had acquired new instruments in pharmaceutical care and had improved
their relationship with their customers. They also reported that patients appreciated this free
and customized intervention that made them feel cared for. The most frequently raised criti-
cism was the difficulty in involving GPs.
Table 3. Individual characteristics associated to non-adherence to prescribed oral therapy and recommended clinical examinations.
Oral therapy (n = 834) HbA1c (n = 930) GCI (n = 930)
PR 95% CI PR 95% CI PR 95% CI
Gender
Women 1 1 1
Men 0.86 0.59–1.27 1.27 0.99–1.63 1.25 1.01–1.56
Age
�65 1 1 1
55–64 1.25 0.79–1.97 0.92 0.69–1.23 0.86 0.66–1.11
45–54 2.23 1.36–3.65 0.74 0.47–1.16 0.95 0.68–1.33
<45 2.14 0.99–4.64 0.85 0.40–1.83 0.84 0.42–1.65
Duration of diabetes (years)
>10 1 1 1
6–10 0.77 0.44–1.35 1.33 0.99–1.80 1.46 1.12–1.91
1–5 1.74 1.10–2.76 1.55 1.15–2.08 1.67 1.28–2.17
<1 1.54 0.82–2.92 0.94 0.55–1.63 1.34 0.87–2.05
Unknown 1.08 0.48–2.43 1.28 0.80–2.03 1.72 1.20–2.49
Comorbidities
No 1 1 1
Yes 1.03 0.62–1.71 0.77 0.56–1.07 0.81 0.61–1.08
Educational level
High 1 1 1
Medium 0.72 0.45–1.14 1.10 0.77–1.55 1.10 0.82–1.49
Low 0.92 0.55–1.54 1.49 1.06–2.10 1.46 1.09–1.96
Living alone
No 1 1 1
Yes 0.85 0.44–1.64 1.09 0.75–1.60 1.01 0.71–1.42
Social network
Yes 1 1 1
No 0.47 0.20–1.14 0.62 0.38–1.03 0.77 0.53–1.13
Study area
BAT 1 1 1
BR 1.31 0.88–1.95 1.35 1.06–1.75 1.25 1.00–1.56
Umbria 0.66 0.40–1.07 0.55 0.40–0.75 0.55 0.42–0.72
Prevalence Ratios (PR) estimated by multivariate robust Poisson models.
https://doi.org/10.1371/journal.pone.0256478.t003
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Discussion
Summary of results
This study confirms that community pharmacies and pharmacists are a good setting for con-
ducting investigations as their project participation is generally very high, as has already been
reported [23,28]. Moreover, more than nine hundred diabetic patients were intercepted and
agreed to be interviewed.
In the populations covered by the study, we found very low rates of non-adherence to pre-
scribed pharmacological treatments, ranging from an average of 8% for insulin to 13% for oral
antidiabetic drugs. Conversely, rates of adherence to the clinical examinations recommended
by the guidelines for follow-up–although they were on average above 70%–may be improved,
particularly with regards to the combination of different examinations, as captured by the
composite indicator (non-adherence goes from 11 to 29%). Age and duration of diabetes were
the most significant predictors of non-adherence, but also educational level and geographical
area had an independent impact.
Possible explanations
Previous population-based studies had reported adherence to drugs ranging from 20% to 80%
[4], and from 28% to 36% when the composite indicator of clinical follow-up was considered
[3,5,6]. Higher adherence rates have been reported for the HbA1c and cholesterol tests, taken
singularly, but they hardly reached such high values as in our study [3,5–8]. Compared to
adherence estimated at the population level, our data show that patients who go to a pharmacy
are likely to be selected among those who are more adherent and therefore less in need of a
reinforcement intervention, particularly for drug therapies. Although this was a foreseen
intrinsic characteristic of the enrolment strategy (patients entering a pharmacy to acquire
drugs for diabetes), previous experiences in Piedmont had shown a higher prevalence of non-
adherence [18,29], leaving more space for improvement via the professional counselling of
pharmacists. Unfortunately, most of the non-adherent patients at baseline did not return to
the pharmacy for the requested feedback, therefore it was not possible to measure and evaluate
the effect of the counselling.
As regards the impact of age and duration of disease on adherence, the literature is not con-
sistent, mainly because of the multifaceted nature of the phenomenon; therefore, disentangling
the impact of single factors is difficult [30,31]. In our study, non-adherence to prescribed oral
therapies is higher in young and recently diagnosed subjects. Awareness of one’s health may
actually increase with age and disease duration, but a selective survival mechanism cannot be
excluded; less adherent patients may have died earlier and are therefore not found among the
older patients or with longer durations of disease. Our results also suggest the existence of an
intermediate period of disease duration, during which patients have a decline in their attention
to controlling their disease, which was also shown for the recommended clinical examinations.
It might therefore be more effective to plan possible reinforcement interventions in relation to
the duration of the disease, in order to underly the importance of maintaining high adherence
to both drugs and clinical follow-up since the first diagnosis. Analogously, more counselling
could be specifically addressed to younger patients.
We observed large geographical differences, with higher levels of adherence in Umbria,
which suggest that either much more selective recruitment or higher adherence levels were
present in the catchment area of the participating pharmacies. Indeed, the different organiza-
tion of diabetic patient care in the different local health systems may also explain the geograph-
ical differences, particularly in clinical follow-up. Whatever mechanism is in place, high
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adherence rates provide little room for improvement, meaning that any such intervention
would have low efficiency. This therefore suggests the need to identify in advance the areas
where such an intervention would result to be more effective.
Interestingly, we observed a significant excess of non-compliance to the recommended clin-
ical follow-up examinations among people with lower educational qualifications. This indi-
cates that interventions aimed at increasing adherence to a correct therapeutic pathway could
be specifically tailored towards less educated patients, and thus may contribute to reducing
inequalities in the negative outcomes of the disease.
A further interesting result that should be considered in the overall evaluation of the pro-
gramme is that pharmacists showed great satisfaction and felt that they had improved their
relationship with customers with the benefit of their greater loyalty to the pharmacy.
Limitations and strengths
The main limitation of this study, as has already been discussed, was the enrolment of patients
with high levels of adherence and, moreover, the difficulty faced in tracing and making
patients return to the pharmacy for follow-up, particularly in the case of the few non-adherent
patients at baseline. This suggests that monitoring and enhancing adherence do not work
properly in the usual operating setting of the pharmacy. In similar future projects, it would be
necessary to enrol patients using strategies that identify subjects at higher risk of non-adher-
ence or to shift focus by addressing patients at risk of therapeutic inappropriateness. This
could be achieved via improved interaction between GPs and pharmacies in order to build
integrated care pathways that include all the actors of primary care. One strength of this proj-
ect was, indeed, the use of common software for collecting data in a harmonized database in
all pharmacies; the same platform could be used for sharing patient information between
health professionals.
A possible bias may derive from the instrument used to assess drug adherence. Indeed, sim-
ilarly to what suggested in the literature [32], we used a 4-item questionnaire because of its
brevity and acceptability; on the other hand, it investigates only some macro-aspects of non-
adherence, such as having forgotten or voluntarily interrupted taking drugs, and this may have
underestimated the number of non-adherent patients. However, in a subsequent sensitivity
analysis, we found that even with a lower non-adherence cut-off (score> 0, hence higher
rates), multivariable models on the determinants of non-adherence yielded substantially the
same results. The original 8-item Morisky questionnaire [33], which also enquires as to specific
situations of occasional non-adherence, or other possible tools could be tested in future
studies.
Conclusions
This study aimed to assess the transferability and efficacy of a community pharmacy pro-
gramme for tertiary prevention among patients with type 2 diabetes. It provided us with some
key information, which could be useful for future intervention planning.
The first lesson learned from our study is that the enrolment of subjects with poor adher-
ence to drug therapies is not easy in the usual operating setting of pharmacies. Therefore, it is
necessary to improve the methods for identifying therapeutic inappropriateness and intercept-
ing non-adherent patients. On the other hand, while non-adherence to recommended clinical
examinations is more easily identifiable in community pharmacies, it is necessary to
strengthen collaboration with GPs if corrective mechanisms are to be found. Analogously, the
involvement of different areas of the country has allowed us to understand the importance of
planning similar interventions in areas where possible problems of adherence to therapeutic
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pathways are highlighted in advance, in order to maximize the preventive impact of pharma-
cists’ counselling.
Secondly, the planned evaluation of the effectiveness of counselling for non-adherent
patients could not be fully performed. Indeed, only one third of patients returned to the phar-
macies for follow-up. Furthermore, most of these were already adherent at baseline, making it
impossible to evaluate any possible change in adherence following the pharmacist’s interven-
tion. Nonetheless, pharmacists reported an improved relationship with their customers, which
suggests that similar programmes, developed within community pharmacies, could act as a
lever to improve patient confidence and loyalty, and ensure the greater effectiveness of phar-
macists’ counselling.
Finally, we should recall that these are the results of a "stand-alone" intervention of pharma-
cists. The full potential of the involvement of pharmacists in the health service could be
exploited in structured territorial processes of support to chronic patients.
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